Scholars Central

PerspectivePublished 25 Mar 2022

Nanomedicines that target dendritic cells to induce immunological tolerance

Authors: Stephen Ford

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Induced tolerogenic dendritic cells are a promising treatment for an autoimmune illness that has shown potential in disease models in the lab and early clinical studies. Tolerogenic immunotherapy, in contrast to traditional immunosuppressive therapies, uses the immune system's cells and functions to inhibit the autoreactive lymphocytes that cause illness and damage. The fundamental procedures for isolating and reprogramming Dendritic Cells (DCs), which are at the heart of this strategy, are well understood. The expensive cost and customized nature of this technology, however, limit its wider adoption. By executing this reprogramming process in situ, nanomedicine provides an alternate way. The problems and potential of employing nanoparticles as a delivery method to target DCs and induce immunomodulation are discussed in this paper, with an emphasis on their adaptability. The potential for them to overcome crucial challenges in organ transplantation and increasingly common autoimmune conditions like type 1 diabetes and multiple sclerosis, where novel immunotherapy techniques have begun to show promise, is then highlighted.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Nanoscience and Nanomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nanoscience and Nanomedicine
  • SubjectNanotechnology
  • BylineArticles whose byline prints “Stephen Ford”